Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TAF1 | P21675 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 5/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861413 | 0.85 | BRD4 (0.32) | POLBALDH1A1MAPTBRD4TAF1 | |
| SCHEMBL27989702 | 0.83 | BRD4 (0.32) | POLBCYP3A4CYP2B6ALDH1A1MAPT | |
| SCHEMBL2930014 | 0.83 | BRD4 (0.32) | POLBALDH1A1MAPTBRD4TAF1 | |
| SCHEMBL6864577 | 0.80 | CDK4 (0.35) | ALDH1A1MAPTKDM4EGAABRD4 | |
| SCHEMBL27628887 | 0.80 | MAPT (0.38) | POLBALDH1A1MAPTKDM4EGAA | |
| SCHEMBL5479286 | 0.78 | ALDH1A1 (0.38) | POLBALDH1A1MAPT | |
| SCHEMBL301397 | 0.75 | ALDH1A1 (0.35) | POLBALDH1A1MAPTKDM4E | |
| SCHEMBL28328177 | 0.75 | GPR84 (0.31) | — | |
| SCHEMBL725456 | 0.74 | ALDH1A1 (0.41) | POLBALDH1A1MAPT | |
| SCHEMBL31038033 | 0.72 | POLB (0.43) | POLBALDH1A1MAPTJAK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025027567-A1 | PROCESS FOR PREPARING MAVACAMTEN AND PROCESS INTERMEDIATE | OLON S.P.A. (IT) | 2025-02-06 | — | — | WO | disclosed |
| CN-119118931-A | Barbituric acid derivative and preparation method thereof | 武汉绿合医药科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119039236-A | Benzamidopyrimidinedione derivative and application thereof | 石家庄迪斯凯威医药科技有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-118373777-A | Pyrimidine diketone derivative and preparation method and application thereof | 河北科技大学 | 2024-07-23 | — | — | CN | disclosed |
| CN-109384729-B | Pyrimidinedione compounds for cardiac disorders | 迈奥卡迪亚公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022263829-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-12-22 | — | — | WO | disclosed |
| CN-114945372-A | Methods of treatment with myosin modulators | 迈奥卡迪亚公司 | 2022-08-26 | — | — | CN | disclosed |
| WO-2022111498-A1 | PYRIMIDINEDIONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-11084829-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-7834000-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834000-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
| EP-1758895-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006009734-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1169310-A1 | PROCESS FOR PREPARING MKC-442 | Triangle Pharmaceuticals Inc. (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061566-A1 | PROCESS FOR PREPARING MKC-442 | TRIANGLE PHARMACEUTICALS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| US-5889013-A | REACTING AN URACIL COMPOUND WITH N, O-BIS/TRIMETHYLSILYL/ACETAMIDE FOLLOWED BY TETRABUTYLAMMONIUM IODIDE AND CHLOROMETHYL ETHER COMPOUND AND THEN REACTING WITH ARYL SELENOL IN A BASE | SUNKYONG INDUSTRIES CO., INC. (KR) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, GRPR | POLB 4352/4885CYP3A4 3868/4885CYP2B6 2774/4885 |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | POLB 2883/4885CYP3A4 3186/4885CYP2B6 3963/4885 |
| US-11084829-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | USP7, SENP7, USP8 | POLB 2883/4885CYP3A4 3186/4885CYP2B6 3963/4885 |
| US-20080004261-A1 | CGRP receptor antagonists | CALCRL, CALCR, GRPR | POLB 4352/4885CYP3A4 3868/4885CYP2B6 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.